Sarepta Therapeutics (NASDAQ:SRPT) Research Coverage Started at Jefferies Financial Group

Research analysts at Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $165.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s price target suggests a potential upside of 28.48% from the company’s previous close.

A number of other brokerages have also issued reports on SRPT. Raymond James reiterated an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Citigroup cut their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Cantor Fitzgerald restated a “neutral” rating and set a $152.00 target price on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Finally, Royal Bank of Canada upped their target price on shares of Sarepta Therapeutics from $181.00 to $182.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Two analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $182.95.

Sarepta Therapeutics Stock Up 0.9 %

Shares of SRPT opened at $128.42 on Monday. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The firm has a market cap of $12.14 billion, a P/E ratio of 1,167.45 and a beta of 0.82. The company’s 50-day moving average price is $128.97 and its 200 day moving average price is $132.40. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.27) earnings per share. On average, sell-side analysts forecast that Sarepta Therapeutics will post 1.45 earnings per share for the current year.

Insider Activity

In other news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC lifted its holdings in shares of Sarepta Therapeutics by 59,222.7% during the third quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock worth $9,483,000 after purchasing an additional 75,805 shares during the period. Bank Pictet & Cie Europe AG lifted its holdings in shares of Sarepta Therapeutics by 27.7% during the third quarter. Bank Pictet & Cie Europe AG now owns 2,827 shares of the biotechnology company’s stock worth $353,000 after purchasing an additional 613 shares during the period. Blue Trust Inc. lifted its holdings in shares of Sarepta Therapeutics by 896.5% during the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 511 shares during the period. VitalStone Financial LLC acquired a new stake in shares of Sarepta Therapeutics during the third quarter worth $327,000. Finally, UMB Bank n.a. lifted its holdings in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 197 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.